Australia - engelsk - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - timolol maleate, quantity: 3.4 mg/ml (equivalent: timolol, qty 2.5 mg/ml) - eye drops, solution - excipient ingredients: water for injections; dibasic sodium phosphate dodecahydrate; sodium hydroxide; monobasic sodium phosphate dihydrate; benzalkonium chloride - timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure.,in clinical trials it has been shown to reduce intraocular pressure in:,patients with ocular hypertension,patients with chronic open-angle glaucoma,aphakic patients with glaucoma.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - timolol maleate, quantity: 3.4 mg/ml (equivalent: timolol, qty 2.5 mg/ml) - eye drops, solution - excipient ingredients: benzalkonium chloride; dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; sodium hydroxide; water for injections - timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure.,in clinical trials it has been shown to reduce intraocular pressure in:,patients with ocular hypertension,patients with chronic open-angle glaucoma,aphakic patients with glaucoma.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: benzalkonium chloride; water for injections; dibasic sodium phosphate dodecahydrate; sodium hydroxide; monobasic sodium phosphate dihydrate - timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure.,in clinical trials it has been shown to reduce intraocular pressure in:,patients with ocular hypertension,patients with chronic open-angle glaucoma,aphakic patients with glaucoma

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: water for injections; monobasic sodium phosphate dihydrate; sodium hydroxide; benzalkonium chloride; dibasic sodium phosphate dodecahydrate - timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure.,in clinical trials it has been shown to reduce intraocular pressure in:,patients with ocular hypertension,patients with chronic open-angle glaucoma,aphakic patients with glaucoma

USA - engelsk - NLM (National Library of Medicine)

rising pharma holdings, inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see warnings] ; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see warnings] ; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

viatris sante - bimatoprost 0; timolol 5 mg sous forme de : maléate de timolol 6 - collyre - 0,3 mg - pour 1 ml de solution > bimatoprost 0,3 mg > timolol 5 mg sous forme de : maléate de timolol 6,8 mg - préparation ophtalmologique – antiglaucomateux et myotiques. agents bétabloquants - code atc : s01ed51. - classe pharmacothérapeutique : médicaments ophtalmologiques – bétabloquants - code atc : s01ed51bimatoprost/timolol viatris 0,3 mg/ml + 5 mg/ml, collyre en solution contient deux substances actives différentes (bimatoprost et timolol) qui réduisent toutes deux la pression dans l’œil. le bimatoprost, analogue de la prostaglandine, appartient à un groupe de médicaments appelés prostamides. le timolol appartient à un groupe de médicaments appelés bétabloquants.l’œil contient un liquide aqueux et transparent qui nourrit l'intérieur de l'œil. ce liquide est constamment évacué de l'œil et du nouveau liquide est produit pour le remplacer. si le liquide ne peut pas être évacué suffisamment vite, la pression à l'intérieur de l'œil augmente, ce qui risque éventuellement à la longue d’endommager la vue (une maladie appelée glaucome). bimatoprost/timolol viatris 0,3 mg/ml + 5 mg/ml, collyre en solution agit en réduisant la production de liquide et également en augmentant la quantité de liquide évacué. cela diminue la pression à l'intérieur de l'œil.le collyre bimatoprost/timolol viatris 0,3 mg/ml + 5 mg/ml, collyre en solution est utilisé pour traiter la pression élevée dans l’œil chez l’adulte y compris le sujet âgé. cette pression élevée peut entraîner un glaucome. votre médecin vous prescrit bimatoprost/timolol viatris 0,3 mg/ml + 5 mg/ml, collyre en solution quand les autres collyres contenant des bétabloquants ou des analogues des prostaglandines seuls n’ont pas été assez efficaces.

Singapore - engelsk - HSA (Health Sciences Authority)

pharmaforte singapore pte ltd - timolol maleate 6.84mg/ml eqv. to timolol - solution - 5.00mg/ml - timolol maleate 6.84mg/ml eqv. to timolol 5.00mg/ml

USA - engelsk - NLM (National Library of Medicine)

sandoz inc - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see warnings ] ; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see warnings ] ; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. read this instructions for use that comes with timolol maleate ophthalmic solution before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your doctor about your medical condition or treatment. important information about timolol maleate ophthalmic solution: how should i use timolol maleate ophthalmic solution? the bottle is designed to assure the delivery of a precise dose of medication. before

USA - engelsk - NLM (National Library of Medicine)

oceanside pharmaceuticals - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see warnings] ; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see warnings] ; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. timolol maleate ophthalmic solution 0.25% and 0.5% read this instructions for use that comes with timolol maleate ophthalmic solution before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your doctor about your medical condition or treatment. important information about timolol maleate ophthalmic solution: how should i use timolol maleate ophthalmic solution? step 1. wash

USA - engelsk - NLM (National Library of Medicine)

bausch & lomb americas inc. - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution 0.5% is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic solution 0.5% is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease  [see warnings and precautions( 5.1, 5.3)] . timolol maleate ophthalmic solution 0.5% is contraindicated in patients with sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock  [see warnings and precautions (5.2)] . timolol maleate ophthalmic solution 0.5% is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this product in the past. teratogenic effects teratogenicity studies have been performed in animals. teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. doses of 1,000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity. there are no adequate and well-controlled studies in pregnant women. timolol maleate ophthalmic solution 0.5% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. timolol has been detected in human milk following oral and ophthalmic drug administration. because of the potential for serious adverse reactions from timolol maleate ophthalmic solution 0.5% in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. safety and effectiveness in pediatric patients have not been established. no overall differences in safety or effectiveness have been observed between elderly and younger patients.